Lawrence Mark Nogee, M.D.

Lawrence Nogee’s clinical and research interests are in lung diseases in newborns as well as older children, with a particular focus on genetic lung diseases. His laboratory research focuses on identifying genetic mechanisms leading to neonatal respiratory failure and diffuse and interstitial lung diseases in older infants and children. This includes understanding the biology, molecular epidemiology and pathophysiology of lung diseases due to genetic surfactant dysfunction through molecular and genetic analyses of samples from individuals with these rare lung disorders.

In addition, his laboratory actively seeks to identify novel genetic causes of childhood interstitial lung disorders, determine the role of genetic variants in surfactant-related genes in contributing to more common neonatal lung diseases, and use the study of these disorders to improve our understanding of normal surfactant metabolism. Long-term goals include translating basic science findings into improved diagnostic tests for rare neonatal and diffuse lung disease, and developing more effective therapies for these disorders, and he is part of a multicenter collaboration to develop specific therapy for ABCA3 deficiency, the most common cause of genetic surfactant dysfunction.

Dr. Nogee is an active participant in the Children’s Interstitial Lung Disease Research Network (ChILDRN) and part of the Johns Hopkins Center for Pulmonary Hypertension and Congenital Diaphragmatic Hernia working groups, is a site co-investigator on a multicenter trial of treprostinil as add-on therapy for persistent pulmonary hypertension of the newborn, and a co-investigator on the NIH-funded trial evaluating serial amnioinfusions to rescue the lethal pulmonary hypoplasia associated with early-onset anhydramnios (PI: Eric Jelin, general pediatric surgery).